ESSA Pharma Inc. (EPIX) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ESSA Pharma Inc. reports promising results from its ongoing clinical trials evaluating the combination of masofaniten with enzalutamide in prostate cancer patients, with a majority showing significant reductions in PSA levels. The company is on track to complete enrollment for its Phase 2 study in early 2025 and expects to provide preliminary data by mid-year, while maintaining sufficient cash to fund operations beyond 2025.
For further insights into EPIX stock, check out TipRanks’ Stock Analysis page.